Table 1 Clinical features of K. pneumoniae infections
Variable | Nosocomial | HCA | CA | P-value | ||
|---|---|---|---|---|---|---|
(n = 98) | (n = 195) | (n = 86) | HCA versus Nosocomial | CA versus Nosocomial | CA versus HCA | |
Age (years) | Â | Â | Â | Â | Â | Â |
 ≤ 1 | 21 (21.4%) | 12 (6.2%) | 5 (5.8%) | 0.000 | 0.002 | 0.912 |
 2–10 | 10 (10.2%) | 5 (2.6%) | 1 (1.2%) | 0.005 | 0.010 | 0.671 |
 11–18 | 8 (8.2%) | 1 (0.5%) | 2 (2.3%) | 0.001 | 0.107 | 0.223 |
 19–59 | 34 (34.7%) | 89 (45.6%) | 48 (55.8%) | 0.073 | 0.004 | 0.116 |
  ≥ 60 | 25 (25.5%) | 88 (45.1%) | 30 (34.9%) | 0.001 | 0.166 | 0.109 |
Sex | Â | Â | Â | Â | Â | Â |
 Male | 56 (57.1%) | 131 (67.2%) | 56 (65.1%) | 0.092 | 0.269 | 0.736 |
Infection type | Â | Â | Â | Â | Â | Â |
 Respiratory tract | 23 (23.5%) | 66 (33.9%) | 18 (20.9%) | 0.068 | 0.68 | 0.029 |
 Bloodstream | 45 (45.9%) | 35 (18.0%) | 7 (8.1%) | 0.000 | 0.000 | 0.034 |
 Urinary tract | 9 (9.2%) | 46 (23.6%) | 18 (20.9%) | 0.003 | 0.025 | 0.624 |
 Cerebra | 5 (5.1%) | 3 (1.5%) | 0 (0.0%) | 0.123 | 0.034 | 0.555 |
 Skin and soft tissue | 3 (3.1%) | 16 (8.2%) | 22 (25.6%) | 0.092 | 0.000 | 0.000 |
 Oral cavity | 5 (5.1%) | 3 (1.5%) | 1 (1.2%) | 0.123 | 0.217 | 1.000 |
 Other | 8 (8.2%) | 16 (8.2%) | 11 (12.8%) | 0.990 | 0.303 | 0.229 |
 liver | 0 (0.0%) | 1 (0.5%) | 4 (4.7%) | 1.000 | 0.031 | 0.032 |
 Biliary tract | 0 (0.0%) | 9 (4.6%) | 5 (5.8%) | 0.032 | 0.016 | 0.767 |
Underlying disease | Â | Â | Â | Â | Â | Â |
 Solid tumor | 7 (7.1%) | 20 (10.3%) | 5 (5.8%) | 0.385 | 0.716 | 0.264 |
 Diabetes mellitus | 8 (8.2%) | 34 (17.4%) | 24 (27.9%) | 0.033 | 0.000 | 0.055 |
 Pulmonary disease | 1 (1.0%) | 7 (3.6%) | 5 (5.8%) | 0.276 | 0.099 | 0.522 |
 Hematological malignancy | 25 (25.5%) | 23 (11.8%) | 3 (3.5%) | 0.003 | 0.000 | 0.027 |
 Brain tumor | 10 (10.2%) | 7 (3.6%) | 2 (2.3%) | 0.022 | 0.031 | 0.727 |
 Cerebral vascular disease | 13 (13.3%) | 47 (24.1%) | 10 (11.6%) | 0.030 | 0.738 | 0.017 |
 Hepatobiliary disease | 7 (7.1%) | 13 (6.7%) | 8 (9.3%) | 0.879 | 0.593 | 0.439 |
 Chronic kidney disease | 4 (4.1%) | 21 (10.8%) | 7 (8.1%) | 0.053 | 0.247 | 0.498 |
 Cardiovascular disease | 4 (4.1%) | 20 (10.3%) | 5 (5.8%) | 0.069 | 0.736 | 0.228 |
 Hypertension | 18 (18.4%) | 61 (31.3%) | 17 (19.8%) | 0.019 | 0.852 | 0.047 |
 Immunosuppression | 29 (29.6%) | 38 (19.5%) | 6 (7.0%) | 0.052 | 0.000 | 0.008 |
Prior antibiotic exposure | Â | Â | Â | Â | Â | Â |
 Any antibiotic | 53 (54.1%) | 115 (59.0%) | 0 (0.0%) | 0.424 | 0.000 | 0.000 |
 1st or 2nd generation cephalosporin | 6 (6.1%) | 7 (3.6%) | 0 (0.0%) | – | – | – |
 3rd or 4th Generation cephalosporin | 10 (10.2%) | 17 (8.7%) | 0 (0.0%) | – | – | – |
 β-lactam and β-lactamase inhibitor | 14 (14.3%) | 19 (9.7%) | 0 (0.0%) | – | – | – |
 Carbapenem | 17 (17.4%) | 21 (10.8%) | 0 (0.0%) | – | – | – |
 Fluoroquinolone | 2 (2.0%) | 5 (2.6%) | 0 (0.0%) | – | – | – |
 Aminoglycoside | 2 (2.0%) | 3 (1.5%) | 0 (0.0%) | – | – | – |
 Tigecycline | 3 (3.1%) | 3 (1.5%) | 0 (0.0%) | – | – | – |
 Glycopeptide | 7 (7.1%) | 12 (6.2%) | 0 (0.0%) | – | – | – |
 Metronidazole | 0 (0.0%) | 1 (0.5%) | 0 (0.0%) | – | – | – |
30-day crude mortality | 19 (19.4%) | 24 (12.3%) | 4 (4.7%) | 0.106 | 0.003 | 0.048 |